Bridging Innovators: Wallonia-UK Advanced Therapies Mission 2024

30 Sept – 3 Oct 2024 | United Kingdom

ExpertiseUpdated on 9 September 2024

Viral vector development for gene delivery/gene therapy

Benjamin DAMIEN

CEO at SAGITTA BIOTECH

Liège, Liège, Belgium

About

Sagitta's viral vector have a large payload capacity (up to 18kbp), and can express affinity proteins in order to infect only cells carrying specific markets (tumor marker, cell type, etc).

In addition, Measles surface proteins have been removed, to avoid pre-existing MV immunity. The vector do not elicit any neutralizing immune response.

Our technology has the capacity to offer several benefits over Adeno/AAV technologies, and we are looking for partners to explore this opportunity.

Similar opportunities